Jeff Michaels, OD, MBA, FAAO: CSI Dry Eye Software: Speaker's Bureau (honoraria or other compensation) (); Lumenis: Speaker's Bureau (honoraria or other compensation) ()
Walt Whitley, OD, MBA, FAAO: AbbVie/Allergan: Advisory Committee/Board Member (), Consulting Fees (); Alcon: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Aldeyra Therapeutics: Consulting Fees (); Apellis Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bruder: Advisory Committee/Board Member (); Dompe: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Epion: Advisory Committee/Board Member (); Glaukos: Consulting Fees (); Harrow Pharmaceuticals: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); I2-Vision, Inc: Advisory Committee/Board Member (), Consulting Fees (); Iveric: Consulting Fees (); Lenz: Speaker's Bureau (honoraria or other compensation) (); Mediprint Pharma: Consulting Fees (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Nordic Pharma: Consulting Fees (); Regener-Eyes: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Science Based Health: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Sight Sciences: Consulting Fees (); Sun Pharma: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) (); Tarsus Pharma: Advisory Committee/Board Member (), Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Trukera: Advisory Committee/Board Member (); Viatris: Consulting Fees (); Visus Therapeutics: Advisory Committee/Board Member ()
Ocular surface disease is the most common medical condition seen in eye care today. Recently, the Dry Eye WorkShop III (DEWS III) was released to provide an evidence-base review of the literature as well as a deep dive into where we are in dry eye today. In this course, presenters will discuss differing clinical viewpoints on common dry eye questions and concerns.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Review updates from the DEWS III Report
Gain take home clinical pearls to effectively manage ocular surface diseases
